Puma Biotechnology announces amendment to Neratinib licensing agreement with Pfizer

25-07-2014 Business Wire HealthComments (0)

PfizerPuma Biotechnology

Puma Biotechnology announced that its license agreement with Pfizer for the investigational drug neratinib (PB272) has been amended.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top